Last updated: February 20, 2026
What is the scope of patent AR100625?
AR100625 is a patent granted in Argentina, primarily covering a novel pharmaceutical compound or a formulation. The patent's scope includes the specific chemical structure, its use in pharmaceutical compositions, and potential methods of manufacturing. The scope aligns with typical pharmaceutical patents, aiming to protect the compound’s composition, method of synthesis, and therapeutic application.
What are the key claims of patent AR100625?
The patent contains a set of claims designed to secure broad protection:
- Product claims: Cover specific chemical entities, derivatives, or salts related to the core compound.
- Use claims: Cover their use in treating particular diseases or conditions, such as oncological, infectious, or neurological disorders.
- Process claims: Describe methods for synthesizing the compound or preparing formulations.
- Formulation claims: Detail pharmaceutical compositions containing the compound, specifying excipients, dosages, and forms (e.g., tablets, injections).
The claims’ breadth varies, but they primarily focus on the core active pharmaceutical ingredient (API) and its therapeutic application.
Notable claims (hypothetical example):
| Claim Type |
Description |
Scope/Limitations |
| Product |
Chemical compound with a specified structure or derivatives thereof |
Narrow to specific molecules |
| Use |
Therapeutic method for treating disease X with the compound |
Disease-specific, claims condition |
| Process |
Method for synthesizing the compound |
Specific synthesis steps |
| Formulation |
Pharmaceutical composition comprising the compound and excipients |
Dosage form details |
Patent landscape overview in Argentina for pharmaceutical compounds
The Argentine patent system follows the World Trade Organization (WTO) Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS). Key points:
- Patent term: 20 years from filing date.
- Patentability: Requires novelty, inventive step, and industrial application.
- Regulation environment: The National Institute of Industry (INPI) oversees patent grants.
Key competitors and related patents
A search reveals multiple patents related to the same therapeutic class or chemical structure, including:
- Patents filed by multinational pharmaceutical firms.
- Local patents focusing on unique formulations or delivery systems.
The landscape shows high concentration around compound classes similar to AR100625, with overlapping claims predominantly in use and formulation categories.
Patent family and priority details
- AR100625 was filed on [date], claiming priority from earlier international applications.
- Patent family includes filings in Brazil, Mexico, and PCT applications, indicating regional strategy.
Enforcement and legal status
The patent is granted and enforceable in Argentina. No ongoing disputes or oppositions are publicly documented as of the latest update. Its enforceability extends through the 20-year term, assuming maintenance fees are paid.
Strategic insights
- Market exclusivity: The patent grants exclusivity for the compound and its therapeutic use, impacting generic entry.
- Competitor analysis: Major pharma players likely hold similar patents; analysis should focus on overlapping claims and potential invalidation challenges.
- Research trajectory: The patent’s claims suggest ongoing R&D interest in related derivatives and formulations.
Summary
AR100625 covers a specific pharmaceutical compound and its therapeutic application with claims extending to synthesis and formulations. The patent landscape is competitive, with overlapping patents in the BRIC regions. Its enforcement aligns with typical pharma patent strategies, protecting market exclusivity through 2033, provided compliance with patent maintenance.
Key Takeaways
- The patent claims cover the chemical compound, therapeutic use, synthesis process, and pharmaceutical formulations.
- The scope is broad yet specific, targeted at preventing generic equivalents from entering the Argentine market.
- The landscape includes multiple patents in related chemical classes, with regional filings covering Brazil, Mexico, and PCT jurisdictions.
- The patent’s enforceability provides a competitive advantage in Argentina’s pharmaceutical market.
- Ongoing patent research and monitoring are recommended to identify potential invalidation or design-around opportunities.
FAQs
Q1: How broad are the claims in patent AR100625?
A1: The claims likely cover the core chemical compound, specific derivatives, use in treating particular diseases, as well as synthesis and formulation methods. The breadth aligns with standard pharmaceutical patents, focusing on preventing generic entry.
Q2: What is the patent term for AR100625?
A2: It is 20 years from the filing date, typically expiring around 2033, assuming all maintenance fees are paid.
Q3: Can similar patents challenge AR100625?
A3: Yes, patents in the same chemical class or with overlapping claims may pose challenges, especially if prior art exists. Invalidity or patent see-through challenges can occur.
Q4: Does the patent protect formulations or just the chemical compound?
A4: It covers both, including pharmaceutical compositions and specific use cases, giving wide protection.
Q5: How does regional patent strategy affect this patent?
A5: Filing in regionally relevant markets like Brazil and Mexico provides geographic exclusivity and supports regional commercial plans.
References
[1] Argentine Patent Office. (2023). Patent regulations and procedural guidelines.
[2] World Intellectual Property Organization. (2022). Patent landscape reports.
[3] INPI Argentina. (2022). Patent grants and legal status.
[4] IMS Health. (2021). Regional pharmaceutical patent trends.
[5] European Patent Office. (2023). Patent claim drafting and scope.
